A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. - Wikidata - wikimedia - TriplyDB

A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease.

A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease.

http://www.wikidata.org/entity/Q33292093

about

Clinical immunologic approaches for the treatment of Alzheimer's disease Immunotherapy as treatment for Alzheimer’s disease Current Insights into Molecular Mechanisms of Alzheimer Disease and Their Implications for Therapeutic Approaches Vitamin A and Alzheimer's disease TREM2 Variants in Alzheimer's Disease The role of seladin-1/DHCR24 in cholesterol biosynthesis, APP processing and Abeta generation in vivo.Contribution by synaptic zinc to the gender-disparate plaque formation in human Swedish mutant APP transgenic mice Nasal vaccination with a proteosome-based adjuvant and glatiramer acetate clears beta-amyloid in a mouse model of Alzheimer disease Biomarkers of Alzheimer's disease Active and passive immunotherapy for neurodegenerative disorders Prototype Alzheimer's disease epitope vaccine induced strong Th2-type anti-Abeta antibody response with Alum to Quil A adjuvant switch Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage Overcoming antigen masking of anti-amyloidbeta antibodies reveals breaking of B cell tolerance by virus-like particles in amyloidbeta immunized amyloid precursor protein transgenic mice The immunotherapy of Alzheimer's disease The microglial "activation" continuum: from innate to adaptive responses Novel Abeta peptide immunogens modulate plaque pathology and inflammation in a murine model of Alzheimer's disease.Immunotherapy in Parkinson's Disease: Micromanaging Alpha-Synuclein Aggregation Fluid Biomarkers in Clinical Trials of Alzheimer's Disease Therapeutics Alzheimer's therapeutics: translation of preclinical science to clinical drug development Common defects of mitochondria and iron in neurodegeneration and diabetes (MIND): a paradigm worth exploring Preclinical Alzheimer disease: identification of cases at risk among cognitively intact older individuals Insights into the physiological function of the β-amyloid precursor protein: beyond Alzheimer's disease Innate immunity in Alzheimer's disease: a complex affair 'Clinical trials in Alzheimer's disease': immunotherapy approaches Inflammatory events at blood-brain barrier in neuroinflammatory and neurodegenerative disorders: implications for clinical disease Abnormal cognition, sleep, EEG and brain metabolism in a novel knock-in Alzheimer mouse, PLB1 Chronic intranasal treatment with an anti-Aβ(30-42) scFv antibody ameliorates amyloid pathology in a transgenic mouse model of Alzheimer's disease Structural Correlates of Antibodies Associated with Acute Reversal of Amyloid -related Behavioral Deficits in a Mouse Model of Alzheimer Disease His-tag binding by antibody C706 mimics β-amyloid recognition Crystal structure reveals conservation of amyloid-β conformation recognized by 3D6 following humanization to bapineuzumab Alzheimer's disease: Targeting the Cholinergic System Excess cerebral TNF causing glutamate excitotoxicity rationalizes treatment of neurodegenerative diseases and neurogenic pain by anti-TNF agents Immunotherapeutic approaches for Alzheimer's disease Current and future implications of basic and translational research on amyloid-β peptide production and removal pathways Evolving Drug Delivery Strategies to Overcome the Blood Brain Barrier.Stroke, dementia, and drug delivery Dense-core senile plaques in the Flemish variant of Alzheimer's disease are vasocentric Amyloid β: one of three danger-associated molecules that are secondary inducers of the proinflammatory cytokines that mediate Alzheimer's disease Activation of Wnt signaling rescues neurodegeneration and behavioral impairments induced by beta-amyloid fibrils Neuroprotective and neurotoxic properties of glial cells in the pathogenesis of Alzheimer's disease

P2860

Q22241380-FFD0F95B-6B96-4A9E-B514-D3427E8E35D4 Q22241491-F3F8DAD9-D008-4DA6-A5F5-18B25F9B26BF Q22241945-5B220676-C93E-4094-9454-28E062571EA9 Q22242414-E9A88922-398F-4F61-B914-507D0C554020 Q22250873-68A3BE43-1A92-455C-9C19-F5844273BE8D Q24300901-96DA0A7E-E52C-4AC2-B05E-6B3CADC6B4AA Q24530682-6394C09E-4D8D-4AFE-9F46-565132FF399A Q24534813-A6CEECE8-745C-460A-92B2-13BF388A2BE3 Q24650667-B1814A7F-D148-4A02-BD48-79220EFBC894 Q24657879-CFD51AF9-A703-493B-9407-162ED2082C26 Q24676179-7860E55D-A1EB-466F-A86D-18FB17FB3E0A Q24791704-7A0E6262-C949-45B7-9D6C-288D43F701A8 Q24799252-55CC5E81-6084-429F-B3E2-A386296F0FC6 Q24804900-6EE5CE37-E0B3-491F-AE26-9FFDE1EB1016 Q24814335-5AD111D3-5667-443B-A606-C7EBC48F6B70 Q25256570-D38125E5-95AF-408E-B18B-5CCC4246445E Q26781130-ED5D082D-B380-44D3-B1B2-3C094E04277D Q26784569-3CFF448F-9951-4D7B-A609-9D90B29FAE7E Q26829267-A1E7B685-58CD-4D44-AB79-B889892F1588 Q26861082-CA1E5A71-CF21-4834-8746-31E88760BD9B Q26995405-354E6F00-23AB-45E2-9385-55D3F82FD93B Q26999922-79259AA6-8B20-4B25-86DB-E69130F7D444 Q27006944-C901F8FA-19A6-42A3-82BA-FAB970F04A6C Q27008979-065B2CC3-53B3-4791-A009-2F59E3469B99 Q27023953-FA2AAB6F-2BAD-4840-B8B6-DB5C8CC38D0B Q27314013-8BB722A8-CF7E-4C6B-94B0-1A60EBC91D09 Q27349010-24F16B4B-89D9-41E7-B6C5-3ECBAC230B7C Q27658233-86F46978-54DC-43A1-91B1-69152035F478 Q27664463-860C839C-157D-4412-B065-ADC95A3D5156 Q27684692-D6E47F31-8A39-4A2A-A53D-CC226271AE88 Q28070135-A179482A-4034-4BB4-AC14-AD49E922685E Q28075692-B0F8DD00-943E-430A-B0BC-E60D90CAA8E7 Q28081278-134B8D75-6B7C-4FFE-9DDB-514C05FFD016 Q28081678-7FDA2B73-58BD-4251-A45F-E5040371701D Q28082016-8BADF8B3-91C2-4DF9-819D-AC8B8BBFC94E Q28166505-A5C5F614-BC71-4CED-83FE-1B9CAA2B10D7 Q28216994-5DE6CEA3-4DE9-4455-BBDE-4241ACAD3CAD Q28384947-2E51E113-8583-4788-8DE3-D6A028D9B9A6 Q28570115-B29F4D35-9ADA-4172-BDE8-06E6923838B1 Q30054419-F1CCB2E1-5D9B-47C1-A58D-96D917DD59E6

P2860

A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease.

http://www.wikidata.org/entity/Q33292093

description

2000 nî lūn-bûn

@nan

2000 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2000 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2000年の論文

@ja

2000年論文

@yue

2000年論文

@zh-hant

2000年論文

@zh-hk

2000年論文

@zh-mo

2000年論文

@zh-tw

2000年论文

@wuu

name

A beta peptide immunization re ...... model of Alzheimer's disease.

@ast

A beta peptide immunization re ...... model of Alzheimer's disease.

@en

A beta peptide immunization re ...... model of Alzheimer's disease.

@nl

type

label

A beta peptide immunization re ...... model of Alzheimer's disease.

@ast

A beta peptide immunization re ...... model of Alzheimer's disease.

@en

A beta peptide immunization re ...... model of Alzheimer's disease.

@nl

prefLabel

A beta peptide immunization re ...... model of Alzheimer's disease.

@ast

A beta peptide immunization re ...... model of Alzheimer's disease.

@en

A beta peptide immunization re ...... model of Alzheimer's disease.

@nl

P1433

Q33292093-2F4977EA-36B9-4DFF-8EAF-70321BDB2E68

P1476

Q33292093-C895EC90-1FB9-4AC8-BCA1-D87DC971DC10

P2093

Q33292093-0D27A76A-35BA-481D-9356-8226E909497D

Q33292093-55D7B02B-5EF3-4CE3-9EB7-B7B285C2B31A

Q33292093-62526FEF-047B-4EDE-92C9-C0C18785CFA4

Q33292093-7C4F7DA1-F4F5-44C2-9BEB-E45CFEE6F06A

Q33292093-939A9194-C0B0-4AD6-8FB1-1C70C1035489

Q33292093-9E3AFEB9-4026-491B-BD4E-2D1C281DD266

Q33292093-AE006FAB-17CA-4C03-BE17-3541D83C5547

Q33292093-B282D103-F799-4713-8647-B1F1FD57A79B

Q33292093-B749AD88-7367-46C4-BA9D-25869B3F5B0F

Q33292093-C0C4127C-18FD-4AEE-8114-983091438CD5

P2888

Q33292093-A4107D5F-65EF-40CC-9B08-D324D9505581

P304

Q33292093-041168DA-DBD2-42B8-BDA9-04D3B3EEC035

P31

Q33292093-58695580-16A0-42F1-8398-F1530745CC18

P356

Q33292093-1B21B33F-4B54-499A-9A4A-14AC99C711F0

P407

Q33292093-610E4AB4-F796-4868-BF5D-E2098414D238

P433

Q33292093-53FD398F-BB35-4CB0-B2F1-92EA18D7C9E8

P478

Q33292093-1630A6FE-A035-43C7-91A4-73C2D0A92271

P50

Q33292093-F2ECE020-1643-4A40-A229-799AF2D17C4E

P577

Q33292093-F64BF78B-4658-453D-A50E-DD52EA77E3FD

P6179

Q33292093-ACBA86C0-AEAD-48D9-8956-8A3D736F91F5

P698

Q33292093-A4982A18-4B9E-4200-A850-424B0D2DED88

P921

Q33292093-2BCC564C-75F2-4649-8D4B-5A5CC8640125

Q33292093-703B2934-26EE-47D2-8ABD-4F8C1C3F3824

P356

P1433

P1476

A beta peptide immunization re ...... model of Alzheimer's disease.

@en

P2093

Bergeron C

http://www.w3.org/2001/XMLSchema#string

Chishti MA

http://www.w3.org/2001/XMLSchema#string

Fraser PE

http://www.w3.org/2001/XMLSchema#string

French J

http://www.w3.org/2001/XMLSchema#string

Heslin D

http://www.w3.org/2001/XMLSchema#string

Horne P

http://www.w3.org/2001/XMLSchema#string

Janus C

http://www.w3.org/2001/XMLSchema#string

Jiang Y

http://www.w3.org/2001/XMLSchema#string

McLaurin J

http://www.w3.org/2001/XMLSchema#string

Mercken M

http://www.w3.org/2001/XMLSchema#string

P2888

P304

979-982

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/35050110

http://www.w3.org/2001/XMLSchema#string

P407

P433

6815

http://www.w3.org/2001/XMLSchema#string

P478

408

http://www.w3.org/2001/XMLSchema#string

P50

P577

2000-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1032611922

http://www.w3.org/2001/XMLSchema#string

P698

11140685

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease